炎症性腸疾患の治療における空洞のメソポロ性ポリドパミンナノ粒子による腸内神経免疫クロストークの回復
まとめ
この研究は,炎症性腸疾患 (IBD) の標的型投与システムを開発した. このシステムはネズミの腸内神経免疫バランスと腸内細菌の多様性を効果的に回復させ,IBDの新たな治療戦略を提供しました.
科学分野:
- 胃腸内科
- 神経科学
- バイオマテリアル科学
背景:
- 腸内神経免疫の交響は 腸内ホメオスタシスに不可欠です
- 炎症性腸疾患 (IBD) は,神経細胞の喪失と腸内神経系の機能の障害を伴う.
- 神経免疫経路を標的とするIBDの効果的な治療法が必要である.
研究 の 目的:
- IBD治療のための標的付きの共配システムを開発する.
- IBDにおけるピラセタムとガランタミンヒドロブロミドの治療の可能性を調査する.
- 腸内神経免疫ホメオスタシスを回復し 腸内細菌の多様性を回復する
主な方法:
- ホールメソポラスポリドパミンナノ粒子 (HMPDA) をキャリアとして使用した.
- ピラセタムとガランタミンヒドロブロミドは,ペクチンでコーティングされたHMPDAナノ粒子 (Drugs@HMPDA@Pec) を使用して併用されました.
- このシステムは大腸炎のマウスモデルで,大腸への標的投与をテストした.
主要な成果:
- Drugs@HMPDA@Pecは神経幹細胞の分化とM2マクロファージの偏化を促進しました.
- このシステムは神経炎症を抑制し ニューロンの増殖とM2マクロファージの増強を促しました
- また血管新生を阻害し,腸内細菌の多様性を改善し,IBDの優れた治療効果を示した.
結論:
- Drugs@HMPDA@Pecシステムは,IBDのための高度なターゲット付き共同配信プラットフォームです.
- この新しい戦略は 腸内神経ネットワークを修復し 植物多様性を回復します
- このアプローチは腸内神経免疫ホメオスタシスを効果的に維持し,IBD治療の新たな洞察を提供します.
関連する概念動画
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
413
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
413


